Nimotop (Nimodipine)

Nimodipine, the active ingredient in Nimotop, is a calcium channel blocker (dihydropyridine) presented as an intravenous formulation for hospital use. It is employed to prevent cerebral vasospasm following subarachnoid hemorrhage and to support neuroprotection in affected patients.

GNH USA supplies Nimotop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Nimodipine is used in the management of cerebrovascular conditions, particularly to prevent vasospasm.

- Prevention of cerebral vasospasm following subarachnoid hemorrhage: reduces the incidence of delayed ischemic neurological deficits. - Management of acute cerebral vasospasm: provides vasodilation to improve cerebral blood flow. - Neuroprotection after subarachnoid hemorrhage: helps preserve neuronal function during the critical post‑hemorrhage period.

Nimodipine may cause a range of adverse reactions, from mild to serious. Monitoring patients for these events is essential during therapy.

Common Side Effects: - Hypotension: transient lowering of blood pressure. - Headache: mild to moderate intensity. - Flushing: warmth and redness of the skin. - Nausea: occasional upset stomach. - Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring intervention. - Myocardial infarction: rare cardiac event. - Allergic reactions: rash, itching, or anaphylaxis. - Hepatic enzyme elevation: abnormal liver function tests. - Thrombocytopenia: low platelet count.

Before initiating Nimodipine, clinicians should assess patient-specific risk factors and monitor for potential complications.

- Blood pressure monitoring: check regularly to detect hypotension. - Hepatic impairment: use with caution in patients with liver dysfunction. - Severe hypotension: avoid in patients already experiencing low blood pressure. - Concomitant vasodilators: assess risk of additive blood pressure effects. - Pregnancy and lactation: safety not established; weigh benefits against potential risks. - Store at ambient temperature: keep in original container, protect from moisture and light.

Nimodipine can interact with several drug classes, influencing its safety and efficacy.

Major Interactions (Avoid): - Other calcium channel blockers: additive vasodilatory effect may cause severe hypotension. - Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase nimodipine plasma levels. - Nitrates: combined use can precipitate profound hypotension.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may enhance blood‑pressure lowering effect. - Diuretics: can amplify orthostatic hypotension. - Other antihypertensives: monitor for excessive blood‑pressure reduction.